Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radi-Ret Study
DRKS00003246Phase 2Terminated
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- May 2013
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of ranibizumab in Radiation chorioretinopathy (2 arms), sponsored by Charité – Universitätsmedizin Berlin. Started May 2013; status: terminated.
02
Drugs
ranibizumab
03
Conditions
Radiation chorioretinopathy
Beyond the preview
Go deeper on DRKS00003246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00003246.